Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Neurol Sci ; 41(11): 3075-3084, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32524324

RESUMEN

BACKGROUND: Vagal nerve stimulation (VNS) is an effective palliative therapy in drug-resistant epileptic patients and is also approved as a therapy for treatment-resistant depression. Depression is a frequent comorbidity in epilepsy and it affects the quality of life of patients more than the seizure frequency itself. The aim of this systematic review is to analyze the available literature about the VNS effect on depressive symptoms in epileptic patients. MATERIAL AND METHODS: A comprehensive search of PubMed, Medline, Scopus, and Google Scholar was performed, and results were included up to January 2020. All studies concerning depressive symptom assessment in epileptic patients treated with VNS were included. RESULTS: Nine studies were included because they fulfilled inclusion criteria. Six out of nine papers reported a positive effect of VNS on depressive symptoms. Eight out of nine studies did not find any correlation between seizure reduction and depressive symptom amelioration, as induced by VNS. Clinical scales for depression, drug regimens, and age of patients were broadly different among the examined studies. CONCLUSIONS: Reviewed studies strongly suggest that VNS ameliorates depressive symptoms in drug-resistant epileptic patients and that the VNS effect on depression is uncorrelated to seizure response. However, more rigorous studies addressing this issue are encouraged.


Asunto(s)
Epilepsia , Estimulación del Nervio Vago , Antidepresivos , Epilepsia/terapia , Humanos , Calidad de Vida , Resultado del Tratamiento
2.
Medicina (Kaunas) ; 56(5)2020 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-32380778

RESUMEN

Background: Nonagenarians and centenarians (NCs) are an extremely fragile population, particularly in regard to their physical and cognitive function. The aim of this study was to define the neurocognitive profiles among 29 NCs and their 49 younger cohabitants aged 50-75 years from The Cilento Initiative on Aging Outcomes (CIAO) Pilot study in the South of Italy that had provided initial hypotheses regarding positive psychological traits related to exceptional longevity. Methods: During the home visits, lifestyle information with specific questionnaires, functional autonomy and the neuropsychological Mini Mental Scale Examination (MMSE), and the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) scale were obtained by qualified study personnel. The total blood oxidative capacity was also determined by testing the reactive derivative of oxygen metabolites (d-ROM) and by the Biological Antioxidant Potential (BAP). In all individuals, the APOE genotype determination was also performed. Results: All the subjects in both groups showed high adherence to the Mediterranean Diet. None of the NCs had severe cognitive impairment, and a very low incidence of dementia was found. The data obtained on the Activities ed Instrumental Activities of Daily Living (ADL-IADL) scale showed that the majority of NCs (16/29) were autonomous in daily life activities. The comparative assessment of NCs and cohabitants showed no significant differences in the laboratory assessment of oxidative stress and APOE genotype. Conclusion: In the Cilento Region of Southern Italy, NCs seemed to have good cognitive status when compared to younger cohabitants aging 50-65 years without significant differences in oxidative stress markers or APOE genotype. These results might be related to optimal adherence to the Mediterranean diet, although other lifestyle factors and positive personality traits may also contribute to their healthy aging. Further studies on a larger population should be performed to confirm the results of this pilot study.


Asunto(s)
Disfunción Cognitiva/diagnóstico , Longevidad/fisiología , Anciano de 80 o más Años , Envejecimiento/fisiología , Disfunción Cognitiva/epidemiología , Estudios Transversales , Femenino , Servicios de Atención de Salud a Domicilio/estadística & datos numéricos , Humanos , Italia/epidemiología , Masculino , Pruebas Neuropsicológicas , Proyectos Piloto
3.
Eur J Haematol ; 99(4): 306-314, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28646624

RESUMEN

OBJECTIVE: To evaluate the prognostic significance of oxidative stress (OS) and antioxidant defence status measurement in patients with chronic lymphocytic leukaemia (CLL). METHODS: d-ROMs test and BAP test were evaluated at diagnosis of 165 patients with CLL and correlated with clinical-biological features and prognosis. RESULTS: An increased oxidative damage (d-ROMs test) and a reduced antioxidant potential (BAP test) were found in CLL patients than normal controls (P<.0001). CLL patients with higher d-ROMs values had higher number of circulating white blood cells and lymphocytes, and higher values of ß2 -microglobulin. Higher d-ROMs values were found in female (P=.0003), in patients with unmutated IgVH (P=.04), unfavourable cytogenetics (P=.002) and more advanced clinical stage (P=.002). Higher BAP test values were found in patients expressing CD49d (P=.01) and with more advanced clinical stage (P=.004). At a median follow-up of 48 months, CLL patients with d-ROMs ≥418 CARR U were found to have a shorter time to first treatment (TFT) (P=.0002), and a reduced survival (P=.006) than others. CLL patients with BAP test values ≥2155 µmol/L had a shorter TFT (P=.008) and a shorter survival (P=.003). CONCLUSIONS: OS can affect CLL patients by concomitantly increasing reactive oxygen metabolites production and decreasing antioxidant defences.


Asunto(s)
Leucemia Linfocítica Crónica de Células B/diagnóstico , Leucemia Linfocítica Crónica de Células B/metabolismo , Estrés Oxidativo , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores , Femenino , Humanos , Cariotipificación , Leucemia Linfocítica Crónica de Células B/mortalidad , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Oxidantes/metabolismo , Fotometría/métodos , Pronóstico
6.
J Cardiovasc Med (Hagerstown) ; 21(2): 89-98, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31789688

RESUMEN

BACKGROUND: The Cilento region of southern Italy has a high prevalence of nonagenarians and centenarians. Few studies of the oldest old have included echocardiographic and/or electrocardiographic data, in a home-based setting. OBJECTIVES: The objective of this pilot study was to delineate the key lifestyle, medical, echocardiographic, and electrocardiographic features of a sample of nonagenarians and centenarians and their younger cohabitants from Cilento, via a comprehensive, home-based cardiovascular assessment. The ultimate aim is to identify the cardiovascular profile and lifestyle factors associated with longevity. METHODS: Twenty-six nonagenarians and centenarians (mean age 94 ±â€Š3 years) and 48 younger cohabitants aged 50-75 years (mean 62 ±â€Š5) underwent a comprehensive cardiovascular evaluation in their homes. RESULTS: In contrast to their younger cohabitants, nonagenarians and centenarians did not smoke, had lower fasting glucose levels, and lower LDL cholesterol despite being half as likely to be taking statins, and showing similar adherence to a Mediterranean diet. Over half of nonagenarians and centenarians (15/26) remained autonomous with their activities of daily living. Prevalence of self-reported coronary artery disease and stroke among nonagenarians and centenarians was low (11.5%), though a significant number had atrial fibrillation (31%) or congestive heart failure (27%). Although 62% of nonagenarians and centenarians had at least moderate valvular disease on echocardiography, less than 25% of those affected reported dyspnea. CONCLUSION: Nonagenarians and centenarians in the Cilento region had a healthy metabolic profile and a low prevalence of clinical cardiovascular disease. Even among nonagenarians and centenarians with structural heart abnormalities, report of symptoms is low. Larger studies in the Cilento population may help elucidate the mechanisms underlying cardiovascular health in the oldest old.


Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Envejecimiento Saludable , Estilo de Vida Saludable , Longevidad , Factores de Edad , Anciano , Anciano de 80 o más Años , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/fisiopatología , Enfermedades Cardiovasculares/prevención & control , Estudios Transversales , Ecocardiografía , Electrocardiografía , Femenino , Evaluación Geriátrica , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Proyectos Piloto , Prevalencia , Factores Protectores , Medición de Riesgo , Factores de Riesgo
7.
Leuk Lymphoma ; 45(7): 1489-90, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15359655

RESUMEN

We report a case of Guillain-Barré Syndrome (GBS) which appeared after mobilization therapy in a patient with B-cell chronic lymphocytic leukemia (B-CLL). After obtaining a partial remission with four cycles of fludarabine at standard dose, the patient underwent to high-dose Cytoxan in order to mobilize CD34+ hematopoietic progenitor cells. During neutropenia the patient experienced fever of unknown origin (FUO) and subsequently developed GBS with normalization of his neurologic condition after 2 months. It is possible that a viral-induced activation of an antigen-specific T and B-cell clone caused a local inflammation and toxicity of Schwann cells with demyelination and axonal damage with a self-limited course.


Asunto(s)
Síndrome de Guillain-Barré/etiología , Movilización de Célula Madre Hematopoyética , Leucemia Linfocítica Crónica de Células B/terapia , Trasplante de Células Madre de Sangre Periférica/efectos adversos , Vidarabina/análogos & derivados , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Ciclofosfamida/administración & dosificación , Ciclofosfamida/farmacología , Fiebre de Origen Desconocido/complicaciones , Filgrastim , Factor Estimulante de Colonias de Granulocitos/farmacología , Humanos , Leucemia Linfocítica Crónica de Células B/complicaciones , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Persona de Mediana Edad , Proteínas Recombinantes , Trasplante Autólogo , Vidarabina/administración & dosificación
8.
Open Neurol J ; 6: 65-70, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22962564

RESUMEN

The relationship between genetic polymorphisms and migraine as a cause of an increased risk of thrombotic disorders development is still debated In this respect, factor V Leiden, factor V (H1299R), prothrombin G20210A, factor XIII (V34L), ß-fibrinogen, MTHFR (C677T), MTHFR (A1298C), APO E, PAI-1, HPA-1 and ACE I/D seem to play a determinant role in vascular diseases related to migraine. The present review analyzes both the incidence of the above genetic vascular mutations in migraineurs and the most re-cent developments related to genetic polymorphisms and migraine.

9.
CNS Neurol Disord Drug Targets ; 10(5): 621-34, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21631404

RESUMEN

Neuroinflammation is considered a chronic activation of the immune response in the central nervous system (CNS) in response to different injuries. This brain immune activation results in various events: circulating immune cells infiltrate the CNS; resident cells are activated; and pro-inflammatory mediators produced and released induce neuroinflammatory brain disease. The effect of immune diffusible mediators on synaptic plasticity might result in CNS dysfunction during neuroinflammatory brain diseases. The CNS dysfunction may induce several human pathological conditions associated with both cognitive impairment and a variable degree of neuroinflammation. Furthermore, age has a powerful effect on enhanced susceptibility to neurodegenerative diseases and age-dependent enhanced neuroinflammatory processes may play an important role in toxin generation that causes death or dysfunction of neurons in neurodegenerative diseases This review will address current understanding of the relationship between ageing, neuroinflammation and neurodegenerative disease by focusing on the principal mechanisms by which the immune system influences the brain plastic phenomena. Also, the present review considers the principal human neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis and psychiatric disorders caused by aging and neuroinflammation.


Asunto(s)
Envejecimiento/fisiología , Encéfalo/patología , Citocinas/fisiología , Enfermedades Neurodegenerativas/tratamiento farmacológico , Enfermedades Neurodegenerativas/patología , Neuroinmunomodulación/fisiología , Envejecimiento/inmunología , Encéfalo/inmunología , Encéfalo/fisiopatología , Sistema Nervioso Central/inmunología , Sistema Nervioso Central/patología , Sistema Nervioso Central/fisiopatología , Humanos , Enfermedades Neurodegenerativas/fisiopatología , Enfermedades Neurodegenerativas/psicología , Neuroinmunomodulación/efectos de los fármacos , Neuroinmunomodulación/inmunología
10.
Rev Recent Clin Trials ; 6(3): 189-203, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21241238

RESUMEN

The increase in the average lifespan and the consequent proportional growth of the elderly segment of society has furthered the interest in studying ageing processes. Ageing may be considered a multifactorial process derived from the interaction between genetic and environmental factors including lifestyle. There is ample evidence in many species that the maximum age attainable (maximum lifespan potential, MLSP) is genetically determined and several mitochondrial DNA polymorphisms are associated with longevity. This review will address the current understanding of the relationship between ageing and several factors both genetics and life style related. Firstly we focused on the most reliable and commonly shared theories which attempt to explain the phenomenon of ageing as the genetic, cellular, neuroendocrine, immunological and free-radicals related theories. Many studies have shown that most of the phenotypic characteristics observed in the aging process are the result of the occurrence, with age, of a low grade chronic pro-inflammatory status called "inflammaging", partially under genetic control. The term indicate that aging is accompanied by a low degree of chronic inflammatory, an up-regulation of inflammatory response and that inflammatory changes are common to many age-related diseases. In this review special attention was dedicated to diseases related to age as atherosclerosis, cancer and Alzheimer disease. Despite the fact that in recent years many theories about ageing have been developed, we are still far from a full understanding of the mechanisms underlying the ageing process.


Asunto(s)
Envejecimiento/inmunología , Envejecimiento/fisiología , Inflamación/fisiopatología , Envejecimiento/genética , Enfermedad de Alzheimer/etiología , Apoptosis , Aterosclerosis/etiología , Evolución Biológica , Encéfalo/patología , Senescencia Celular/genética , Citocinas/metabolismo , Deshidroepiandrosterona , Ambiente , Radicales Libres/metabolismo , Hormona del Crecimiento , Humanos , Sistema Hipotálamo-Hipofisario/fisiología , Inmunidad Innata , Inflamación/complicaciones , Estilo de Vida , Melatonina , Neoplasias/etiología , Estrés Oxidativo/fisiología , Sistema Hipófiso-Suprarrenal/fisiología , Especies Reactivas de Oxígeno/metabolismo , Linfocitos T/inmunología , Telómero , Timo/fisiología
11.
Vitam Horm ; 69: 297-312, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15196887

RESUMEN

Migraine is a neurovascular syndrome characterized by recurrent headache associated with other symptoms, eventually preceded by aura. This chapter reviews the involvement of some mineral, coenzyme, and vitamin defects in the pathogenesis of migraine headaches and focuses on their potential therapeutic use in the preventive treatment for migraine. The therapeutic potential of magnesium, coenzyme Q(10), riboflavin, and vitamin B(12) can be cautiously inferred from some published open clinical trials; it should, however, be considered that double-blind randomized larger studies are needed to correctly estimate the impact of the placebo effect in these promising therapies.


Asunto(s)
Magnesio/farmacología , Trastornos Migrañosos/prevención & control , Riboflavina/farmacología , Ubiquinona/análogos & derivados , Ubiquinona/farmacología , Vitamina B 12/farmacología , Adulto , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Coenzimas , Femenino , Homocisteína/farmacología , Homocisteína/uso terapéutico , Humanos , Magnesio/uso terapéutico , Masculino , Riboflavina/uso terapéutico , Ubiquinona/uso terapéutico , Vitamina B 12/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA